Core Insights - Artelo Biosciences, Inc. is advancing ART27.13 as a potential treatment for muscle preservation in patients undergoing GLP-1 receptor agonist therapy, addressing a significant unmet need in the biopharma sector [1][4][6] Group 1: Strategic Developments - The initiative is supported by the projected growth of the global incretin market, which could reach $200 billion by 2030, with an estimated 25 million Americans potentially receiving GLP-1 treatment by that year [2] - Artelo's strategy focuses on the intersection of biology, clinical need, and commercial opportunity, aiming to establish a prominent role in the GLP-1 treatment landscape [4][6] Group 2: Clinical and Research Insights - Analyses indicate that loss of lean body mass is a significant issue with GLP-1 therapies, highlighting the need for solutions that can help preserve muscle [3][4] - ART27.13 has shown promising results in interim CAReS data, with patients experiencing an average weight gain of approximately 6% compared to a 5% weight loss in placebo-treated patients [5][7] Group 3: Intellectual Property and Research Initiatives - A provisional patent application has been filed covering the use of cannabinoid receptor agonism to prevent muscle loss associated with GLP-1 therapy [6] - A non-clinical study is set to evaluate ART27.13 in models relevant to GLP-1-associated muscle preservation, further supporting its potential utility [6]

Core Insights - Artelo Biosciences is strategically positioned for growth in the $16.3 billion glaucoma market through a fully funded clinical study, highlighting its multi-platform biotech pipeline across various therapeutic areas [1][2][4] Pipeline Overview - The company is advancing three clinical-stage programs targeting oncology support, neuropathic pain, and CNS disorders, while also expanding its lead compound into ophthalmology [2][3] - Artelo's pipeline is based on the principle of modulating lipid-signaling pathways, particularly the endocannabinoid system, to achieve therapeutic outcomes without CNS liabilities [5] Key Compounds - **ART27.13**: A peripheral CB1/CB2 agonist targeting cancer anorexia cachexia, currently in Phase 1b/2a, with European patent protection until 2041. It has shown a 6.4% weight gain in cancer patients compared to a 5.4% loss in the placebo group [6][8][9] - **ART26.12**: A FABP5 inhibitor for chemotherapy-induced peripheral neuropathy, which has completed Phase 1 with no serious adverse events and is preparing for multiple ascending dose studies [10][11][13] - **ART12.11**: A proprietary CBD/tetramethylpyrazine cocrystal with improved pharmacokinetics, entering Phase 1 with favorable regulatory guidance from the UK MHRA [15][16][17] Regulatory Environment - Recent regulatory shifts, including a Presidential executive order expanding CBD research and a Medicare pilot program for CBD reimbursement, create favorable conditions for Artelo's clinical development [19][20][22] Market Opportunities - The total addressable market for Artelo's programs is significant, with the global glaucoma market projected to reach $16.3 billion by 2033, and a notable unmet need in cancer cachexia due to the lack of FDA-approved treatments [24] Intellectual Property - Artelo's strong patent position provides long-term protection for its compounds, with ART27.13's European patent extending through 2041, enhancing its attractiveness for potential partnerships [25][26] Partnership Signals - The company has received unsolicited partnership inquiries from global pharmaceutical companies, indicating external validation of its scientific credibility and potential for collaboration [27][29] Capital Efficiency - Artelo operates with a lean structure, directing a significant portion of its budget to R&D while minimizing overhead costs, which allows for efficient capital use [33][34] Future Milestones - Key upcoming milestones include the commencement of Phase 1 studies for ART12.11 and multiple ascending dose enrollment for ART26.12, with ongoing Phase 2 trials for ART27.13 [30][31]

S-1 1 artl_s1.htm FORM S-1 As filed with the Securities and Exchange Commission on March 24, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Artelo Biosciences, Inc. (Exact name of registrant as specified in its charter) Nevada 7389 33-1220924 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

S-1/A 1 artl_s1a.htm FORM-S-1/A As filed with the Securities and Exchange Commission on March 24, 2026 Registration No. 333-294506 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Artelo Biosciences, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 7389 33-1220924 (I ...

S-1/A 1 artl_s1a.htm FORM-S-1/A As filed with the Securities and Exchange Commission on March 23 , 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Artelo Biosciences, Inc. (Primary Standard Industrial Classification Code Number) Registration No. 333- 294506 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 7389 33-1220924 ...

March 2026 Corporate Presentation Nasdaq:ARTL Pioneering the Science of Lipid Signaling Modulation to Develop Novel Therapeutics Forward Looking Statements Artelo Biosciences, Inc. (the "Company") cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: those rela ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Artelo Biosciences, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) S-1 1 artl_s1.htm FROM-S-1 As filed with the Securities and Exchange Commission on March 20, 2026 Registration No. 333- (Primary Standard Industrial Classification Code Number) Nevada 7389 33-1220924 (I.R.S. Employer Identification ...

Core Insights - Artelo has entered into a Definitive Investigator-Initiated Study Agreement with the Belfast Health and Social Care Trust to investigate the effects of ART27.13 on intraocular pressure in glaucoma patients, with the first patient expected to be enrolled in Q2 2026 [1][2] Group 1: Study and Development - The study is funded by Glaucoma UK and the HSC R&D Division, marking a significant step in expanding the clinical potential of ART27.13 [1] - Artelo will supply ART27.13 capsules as the Investigational Medicinal Product for the study [2] Group 2: Mechanism of Action - ART27.13 aims to modulate intraocular pressure (IOP) by activating cannabinoid receptors in peripheral tissues, including ocular tissues [3] - Preclinical research indicates that peripheral cannabinoid receptor activity may positively affect aqueous humor dynamics and ocular blood outflow, which are crucial for IOP regulation [3] Group 3: Stock Performance - Artelo's stock is currently trading 77% above its 20-day simple moving average (SMA) and 29.5% above its 100-day SMA, indicating short-term strength [4] - Over the past 12 months, shares have decreased by 59.46%, positioning them closer to their 52-week lows than highs [4] - The Relative Strength Index (RSI) is at 63.94, suggesting the stock is in neutral territory, while the MACD indicates a bullish crossover [5] Group 4: Stock Price Activity - As of the latest publication, Artelo Biosciences shares were up 44.95% at $7.03 [6] - Key resistance level is identified at $7.00, with key support at $5.50 [6]

Industry Overview - The biotech and healthcare sectors are advancing novel therapies and strategic platforms to meet rising demand for targeted treatments and efficient global access, with the biologics market projected to exceed $650 billion by 2030 [1] - Medical tourism is accelerating, showcasing capital-efficient clinical progress and high-growth partnerships in precision medicine, oncology adjuvants, and AI-enabled workforce solutions [1] Artelo Biosciences - Artelo Biosciences is expanding the clinical application of ART27.13 into ophthalmology through a fully funded study with the Belfast Health and Social Care Trust, focusing on its effects on intraocular pressure in glaucoma patients [2] - The study is anticipated to enroll its first patient in Q2 2026, with funding from Glaucoma UK and the HSC R&D Division [2] - ART27.13 offers a novel, non-psychotropic approach to improve aqueous humor dynamics, addressing challenges faced by current therapies [3] Totaligent - Totaligent is pivoting into biologics and medical tourism, with two binding Letters of Intent (LOIs) aimed at integrating its Aetherium Medical platform into GloMed Solutions' operations in APAC, which generates approximately $10 million in annual revenue [4] - The binding call option allows Totaligent to acquire 100% of GloMed within one year post-JV closing, targeting a close around March 22, 2026 [4] - A second LOI for the acqui-hire of Aetherium Medical's team and assets aims to enhance logistics and commercialization for AI-accelerated biologics, with no initial cash outlay [5] AIM ImmunoTech - AIM ImmunoTech has secured final approval from the Japan Patent Office for its proprietary use of Ampligen combined with checkpoint inhibitors in cancer treatment, with broad claims covering multiple cancer types [6] - The patent is set to expire on December 20, 2039, and AIM plans to pursue Japanese Orphan Drug Designation for Ampligen in pancreatic cancer, building on existing designations in the U.S. and EU [6][7] YY Group - YY Group has reinforced its FY2026 revenue guidance of $103–110 million through a strategic investment in Arros AI to enhance recruiting efficiency across sectors [8] - Operational momentum is evident with multiple hotel partnerships and contracts in Hong Kong, Thailand, Malaysia, and Singapore, demonstrating a scalable business model [9]

Core Insights - Artelo Biosciences is entering the ophthalmology market with a clinical study for ART27.13 targeting glaucoma patients, backed by Glaucoma UK and HSC R&D Division, with first enrollment expected in Q2 2026 [1][2][7] Industry Overview - The global glaucoma market was valued at USD 9.46 billion in 2025 and is projected to reach USD 16.31 billion by 2033, growing at a compound annual growth rate of 7.05% [2] - Approximately 145.9 million people were affected by glaucoma in 2021, expected to rise to 166 million by 2026 [2] - In the U.S., 4.2 million adults had glaucoma in 2022, projected to increase to 6.3 million by 2050 [2] Company Strategy - Artelo's entry into the glaucoma space represents a significant diversification of its pipeline without requiring dilutive equity financing [1][7] - The investigator-sponsored trial model allows Artelo to maintain strategic control and data rights while reducing financial burdens [7] Product Differentiation - ART27.13 is a synthetic cannabinoid receptor agonist that modulates intraocular pressure (IOP) without central nervous system side effects, targeting CB2 receptors for anti-inflammatory and neuroprotective effects [5][6] - Current standard treatments primarily focus on lowering IOP, leaving neuroprotective needs unaddressed, highlighting the opportunity for ART27.13 [4][5] Clinical Development - The study will be led by Professor Augusto Azuara-Blanco at Queen's University Belfast, focusing on the effects of ART27.13 on IOP [7] - The cross-over study design enhances statistical power and reduces required enrollment numbers [7] Pipeline and Intellectual Property - ART27.13 is not limited to glaucoma; it has shown positive interim Phase 2 data in cancer-related anorexia, indicating its broader therapeutic potential [8] - Artelo has received a Notice of Allowance from the European Patent Office for ART27.13, extending patent protection through December 2041 [9] Key Milestones - First patient enrollment in the glaucoma pilot study is expected in Q2 2026 [10] - Ongoing Phase 2 CAReS trial for cancer-related anorexia [10] - European patent protection for ART27.13 commercial formulation through 2041 [10]